Not yet. Thanks, Prospern, I'll check CYDY out.
It's been a hard year to find a runner and make good money in biotech. Thus far, CPXX, which I didn't know about, is one of the few big winners. I guess the stock play of the year has been NUGT though. Oh well...
I'm still very optimistic here with MRNS, and you're right, shorts will begin to exit in May. At this market cap, there is a lot of blue sky above us. Much more than what's below us.
Yep, a major lost opportunity.
On another note, they're gonna drop IDRA until the capitulation bottom, even if it takes months. Sad...
hey VA... on a side note, several months ago one of the ihub board regulars was telling everyone to buy NUGT, even mortgage the house if you have to. It was $20 per share then. I should have listened to him!
I do not believe in GALE's science, so the answer is no there. (but I could be wrong lol)
AVXL is either:
1) An elaborate hoax, impeccably played by Missling
2) The most important new drug in decades. If this is true, then one of 2 things could happen:
--A) We have a 10-bagger within weeks or months, when we have good 12-week data released, then big pharma partners, then epilepsy, etc, and then they're off to the races
--B) We get good 12-week data, and retail investors cause a short term rally, BUT.... big pharma and crooks on Wall Street try to destroy them. No partnerships or funding, continued lawsuits, hit articles, etc...until they run out of money, be forced to dilute massively or use the Lincoln Park deal (who would then immediately dump all their shares and cause a stock price plunge). The end game would be to force Anavex to accept a bad deal or a cheap acquisition for big pharma. Fortunately, they have Missling, who might be able to win this war.
Take your pick lol
I forgot to mention that in a behavior trial, open label extension studies are almost never done until after positive trial results. Being blinded, nobody knows whether the placebo effect and/or investigator bias is a factor. It's a different case sometimes with other kinds of trials.
Thanks for your opinion. I respect it. Ganax is not a cure. Even if effective, a researcher wouldn't just stop there and declare victory. He'd move forward to the next frontier. It's his life.
We don't know if patients are allowed to continue open label or have requested it. Marinus isn't involved. Usually we only find this out because a company p.r.'s it to boost their stock price. UCDavis, on the other hand, probably has no reason to disclose this
Hey Jr..... I finally figured out your question. I used bad wording. I meant to say "it is a Positive that they are not doing a new FX trial now with a totally new drug. If they were, that would mean that they've already "moved on" from Ganax to something else, meaning that Ganax was a bust. On the contrary, every indication is that they've still been focusing all their attention on Ganax (and now Hagerman also using Allo also on adults), which is very positive."
My previous post was poorly worded. I am very optimistic about FX trial. We likely won't hit every endpoint, but I expect a phase 3 (or, in my dreams, accelerated approval after this rigorous phase 2).
Yes, we need a solid phase 2 leading to phase 3. Then a positive phase 3. We will go up incrementally with each milestone met.
Well, don't base one's investment decision on that! It's about the science. I expect positive results, although it's unrealistic to expect every endpoint to be met. There are a lot of secondary end points.
The fact that he's presenting isn't necessarily bullish. But the fact that Dr Hagerman was originally scheduled to present but was replaced by Dr Kooy instead IS bullish. Perhaps FRAXA wants Dr Kooy to get the credit and the glory, since he discovered the science.
what can you say, today was lousy. I think the days of obscurity and 25K daily share volume are over. The big boys are here now to play. We are part of the game now. I think daily volume will continue to escalate. The next 6 months will be something.
Yes, interesting post over there at SAGE. It definitely has merit for some biotechs (ZLCS comes to mind). I don't think it applies to SAGE. The anti-seizure properties of the neurosteroids is well- known, with a lot of data to back it up. Yes, maybe post-partum depression was a stretch there. We have had ours too at MRNS (PTSD and infantile spasm). But now we are on the right track, with trials of specific diseases in which GABA receptor dysfunction is well-known, such as fragile x and female infantile epilepsy.
I think it's a game of chicken....someone (or many) trying to accumulate without running up the price, but they're finding it painfully hard to do so. Scarce shares. I think this has been going on for 1-2 months...
True... probably a good thing... Data was weak, 12 patients, not even an appropriate control group or placebo.
Might actually be a good thing for us. Our phase 2 FX trial is rigorous--double blinded, placebo-controlled, 60 kids. A very strong trial. And a tragic disease, like DMD. It would be easy for the FDA to accelerate and approve Ganax for FX after phase 2-- especially after rejecting 2 DMD drugs--to prove they are indeed compassionate.
Yep, a good day for the stock, all things considered.
Maybe tomorrow morning we get a P.R. We've gotten them the last two Tuesday mornings
If SRPT can get FDA approval with their flimsy data, it won't take much to have successful Fragile X results (which, btw, has over twice the prevalence of DMD). Hitting only a few of the endponts may be all we need...
Thanks. I think that most of us here are optimistic about the epilepsy trials. It's Fragile X where the opinions differ here, with some optimistic (like me) and others very skeptical.
And yes, I think Techs has the best DD.
Me too, VA. This is an unusual situation-- if, for example, Ganax doesn't meet the arbitrarily-chosen primary endpoint but does extremely well on many of the secondary endpoints, I still think we will move on to a phase 3 (with realistic targets).